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Background  and  purpose:  Endothelial  dysfunction  may  play  a role  in  the  pathogenesis  of  the  slow  coronary
ﬂow  (SCF)  phenomenon.  A  detailed  examination  of blood  cellular  components  has  not  been  performed
for  this  condition.  We  investigated  the  relationship  between  SCF  and  whole  blood  cell  counts.
Method:  Records  of  17,315  patients  who  underwent  coronary  angiography  between  January  2006  and
December  2012  were  evaluated  retrospectively.  A total of  146  patients  with  SCF were  compared  with
148  patients  with  normal  coronary  arteries  according  to  demographic  data,  complete  blood  count,  and
biochemical parameters.
Results: The  following  parameters  were  signiﬁcantly  higher  in SCF  patients  than  in  patients  with  nor-
mal  coronary  arteries:  percentage  of  smokers  (36.3%  vs.  25%,  p =  0.036),  body  mass  index  (26.69  ±  2.84
vs.  26.07  ± 3.15,  p = 0.049),  white  blood  cells  (WBCs)  (7.52  ± 1.43  ×  103 mm–3 vs.  7.01  ±  1.42 ×  103 mm–3,
p =  0.002),  red  cell  distribution  width  (RDW)  (13.68  ±  1.42%  vs. 13.15  ±  1.13%,  p  < 0.001),  platelets
(250.29  ± 50.96  × 103 mm–3 vs. 226.10  ± 38.02  ×  103 mm–3, p <  0.001),  plateletcrit  (PCT)  (0.214  ± 0.40%  vs.
0.184 ±  0.29%,  p < 0.001),  mean  platelet  volume  (8.63  ± 1.10  fL  vs.  8.22 ±  0.83  fL, p < 0.001),  platelet  distri-
bution  width  (PDW)  (16.58  ± 0.76% vs. 16.45  ± 0.57%,  p = 0.028),  and  neutrophils  (4.44  ±  1.25 ×  103 mm–3
vs.  4.12  ± 1.24  × 103 mm–3, p  = 0.029).  Positive  PCT  values  [odds  ratio  (OR),  4.165;  95%  conﬁdence  inter-
val  (CI), 2.493–6.959;  p <  0.001)  and  RDW  (OR,  1.304;  95%  CI,  1.034–1.645;  p =  0.025)  were  independent
predictors of  SCF.
Conclusion: Although  within  the  normal  range,  the  increased  numbers  of WBCs  and  neutrophils  in  patients
with  SCF suggest  that  SCF  may  be a subclinical  inﬂammatory  condition.  Furthermore,  increased  RDW  and
PDW  in  SCF  patients  may  cause  microvascular  blood  ﬂow  resistance  due  to impaired  cell deformability.
The  PCT  provides  reliable  data  regarding  total  platelet  mass  and  may  be a  useful  predictor  of  SCF.
3  Jap©  201
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The slow coronary ﬂow (SCF) phenomenon is seen on coronary
ngiography as a delayed opaciﬁcation of distal vessels, suggest-
ng increased resistance toward the distal coronary segments,
n the absence of signiﬁcant epicardial coronary stenosis. The
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etiopathogenesis of SCF is unknown, although several studies have
shown that endothelial and microvascular dysfunction, inﬂam-
mation, increased platelet activation, and homocysteine may play
roles in this condition [1–7]. The clinical implications and outcomes
of SCF are usually favorable, but it may  be associated with adverse
cardiac conditions such as recurrent angina pectoris, acute myocar-
dial infarction, hypertension, and sudden cardiac death [8,9].
Microvascular ﬂow resistance can result from changes in
blood rheological properties. Patel et al. showed that increased
red cell distribution width (RDW) was  associated with impaired
deformability of erythrocytes [10]. Variations and heterogeneity
of blood cell shape are expressed by RDW for erythrocytes and
vier Ltd. All rights reserved.
f Cardiology 63 (2014) 112–118 113
p
p
p
i
r
p
M
c
t
a
r
d
n
a
n
e
a
i
s
c
d
o
c
c
c
e
f
t
f
w
a
m
w
e
p
t
i
N
L
r
m
p
w
a
d
>
t
s
e
C
t
t
s
i
v
l
m
Angiographic records of 17,315 patients  who underwent 
corona ry angio grap hy betwee n Janua ry 2006 an d Dece mber 
2012 and were  evaluated retrospectively. 
First stage 
Two cardiologists identified patients with slow coronary flow 
(SCF) phenomenon (519 patients) and those with normal 
coronary arteries(NCA) (765 patients)
from non-digital (paper) records.  
Second stage 
Two different  cardiologists without  knowledge of the 
patients’ an giog raphic diagnoses , collecte d demographic data 
and bi ochemical/hematological laboratory resu lts fro m digital 
records (PC rec ords). 
Third stag e 
Two cardiologists without knowledge of the patients’ angiographic 
diagnoses excl uded patients according to the following criteria: 
SCF group      NCA group 
(n = 29)    Acute corona ry syndrome   (n  = 0)
(n = 19 )    Hemat olog ical disease    (n  = 58)
(n =15)   Oncologi cal disease   (n  = 37)
(n = 24)    Inflammatory disease   (n  = 95) 
(n = 23)    WBC >10,000/mm3 (n = 52)
(n = 35)    Hemoglobin le vels  <1 2 g/dl   (n  = 91)
(n = 25)    Valvular disease     (n  = 34)
(n = 21)   Cardi ac valv e opera tio n   (n  = 54)
(n = 23)    Anticoag ulant  thera py   (n  = 25)
(n = 20)   Ej ectio n fr actio n <50 %   (n  = 31) 
(n = 15)    Renal insuff icienc y   (n  = 21)
(n = 22)    Liver or  thyroid dysfunctio n   (n  = 45)
(n = 14)    Thrombocytopenia/thro mbo cytosis  (n  = 41)
(n = 18)    Missing data     (n  = 33)
SCF group  
216 patients  
NCA grou p 
148 patient s 
SCF grou p 
146 pati ents 
Atheroscle rotic  plaque  and  
coronary ectasia (n = 70 )
Fourth stage 
Two experienced interventional cardiologists, unaware of  the 
demographic/laboratory data, evaluated coro nary angiograp hic image s 
and calculated thrombolysis  in my ocardial infarction frame counts. 
NCA grou p 
148 pati ents I. Akpinar et al. / Journal o
latelet distribution width (PDW) for platelets; however, no such
arameter is available for leucocytes. Cell distribution widths of
latelets and erythrocytes have not been evaluated simultaneously
n patients with the SCF phenomenon. In the present study, the
elationships between cellular components of blood and the SCF
henomenon were investigated.
ethods
The angiographic records of 17,315 patients who underwent
oronary angiography, due to anginal symptoms or positive
readmill exercise and scintigraphy tests, between January 2006
nd December 2012 were evaluated retrospectively. The patient
ecruitment process is shown in Fig. 1. In the ﬁrst stage, two car-
iologists obtained the names and hospital record numbers (ID
umbers) of patients with the SCF phenomenon (519 patients)
nd those with normal coronary arteries (765 patients) from the
on-digital (paper) record ﬁles. In the second stage, two differ-
nt cardiologists, who had no knowledge of the patients’ coronary
ngiographic diagnoses, collected demographic data and biochem-
cal and hematological laboratory results from a digital recording
ystem (PC records). In the third stage, another two different
ardiologists, without knowledge of the patients’ angiographic
ata, assessed all patients and selected those for the study based
n the exclusion criteria. Patients meeting any of the following
riteria were excluded: acute coronary syndrome; hematologi-
al, oncological, or inﬂammatory disease; white blood cell (WBC)
ount >10,000 mm–3; hemoglobin level <12 g/dL; valvular dis-
ase or a cardiac valve operation; anticoagulant therapy; ejection
raction <50%; renal insufﬁciency; liver or thyroid dysfunction;
hrombocytopenia or thrombocytosis; and missing data. In the
ourth stage, two experienced interventional cardiologists, who
ere unaware of the demographic and laboratory data, evalu-
ted coronary angiographic images and calculated thrombolysis in
yocardial infarction (TIMI) frame counts. A total of 70 patients
ith signiﬁcant atherosclerotic plaque and coronary ectasia were
xcluded because these conditions are thought to be present in
atients with a slow blood ﬂow [11,12]. Finally, 146 patients with
he SCF phenomenon and 148 patients with normal coronary arter-
es were included in the study.
Transthoracic echocardiography (Vivid 7 Pro, GE, Horten,
orway) was performed with a 2.4 MHz  phased array transducer.
eft ventricular ejection fraction was estimated using Simpson’s
ule. Patients with arterial blood pressure >140/90 mmHg, as
easured from the brachial artery, and those receiving antihy-
ertensive therapy were considered to be hypertensive. Diabetes
as deﬁned by a fasting blood glucose >126 mg/dL or the use of
ntidiabetic drugs. Patients with total cholesterol >200 mg/dL, low
ensity lipoprotein (LDL)-cholesterol >130 mg/dL, or triglycerides
150 mg/dL, and those using lipid-lowering drugs were considered
o be hyperlipidemic. Past and current smokers were classiﬁed as
mokers. This study was conducted with the approval of the local
thics committee.
oronary angiography
Coronary angiography (Integris BH 5000; Philips, Amsterdam,
he Netherlands) was performed via the femoral artery, using
he standard Judkin’s technique. The angiographic standard frame
peed was 25 frames/s. Coronary angiography images of all patients
ncluded in the study were evaluated by two  experienced inter-
entional cardiologists who were unaware of the demographic and
aboratory data. TIMI frame count values were calculated using the
ethod of Gibson et al. [13].Fig. 1. Patients’ recruitment diagram. WBC, white blood cell count.
Blood tests
Hematological parameters
Complete blood counts, performed using a Beckman Coul-
ter LH 780 Analyzer (Miami, FL, USA), included 22 parameters:
WBC  count, 4.8 × 103 to 10.8 × 103 mm–3; red blood cell count
(RBC), 4.2 × 106 to 6.1 × 106 mm–3; hemoglobin (HGB) con-
centration, 12–18 g/dL; hematocrit (HCT), 37–52%; mean cell
volume (MCV), 80–99 fL; mean cell hemoglobin (MCH), 27–31 pg;
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ean cell hemoglobin concentration (MCHC), 32–36 g/dL; RDW,
1.5–15.5; platelet count (PLT), 150 × 103 to 400 × 103 mm–3;
ean platelet volume (MPV), 7.4–10.4 fL; plateletcrit (PCT); PDW;
ymphocyte count (Lym#), 1.3 × 103 to 2.9 × 103 mm–3; mono-
yte count (Mo#), 0.3 × 103 to 0.9 × 103 mm–3; neutrophil count
Neu#), 2.2 × 103 to 4.8 × 103 mm–3; eosinophil count (Eo#),
.06 × 103 to 0.18 × 103 mm–3; basophil count (Ba#), 0.01 × 103
o 0.03 × 103 mm–3; lymphocyte percentage (Lym%), 20.5–45.5;
onocyte percentage (Mo%), 5.5–11.7; neutrophil percentage
Neu%), 45–75; eosinophil percentage (Eo%), 0.9–2.9; and basophil
ercentage (Ba%), 0.2–1%.
iochemical parameters
The following parameters were analyzed with a Siemens
DVIA 2400 instrument (Tarrytown, NY, USA): fasting glucose
70–105 mg/dL), urea (10–50 mg/dL), creatinine (0.50–1.2 mg/dL),
ric acid (3.4–7.0 mg/dL), aspartate transaminase (AST, 0–38 U/L),
lanine aminotransferase (ALT, 0–41 U/L), total cholesterol
110–200 mg/dL), high density lipoprotein (HDL) cholesterol
35–65 mg/dL), LDL cholesterol (60–130 mg/dL), triglycerides
<150 mg/dL).
tatistical analysisStatistical analyses were performed using SPSS 13.0 for Win-
ows (Chicago, IL, USA) and MedCalc 9.2. Categorical variables are
iven as frequency and percentage. Continuous variables are given
able 1
emographic data and biochemical parameters of the patients.
Slow coronary ﬂow group (n = 146) 
Age (years) 58.4 ± 10.3 
Male,  n (%) 100 (68.5) 
Hypertension, n (%) 79 (54.1) 
Diabetes mellitus, n (%) 41 (28.1) 
Hyperlipidemia, n (%) 46 (31.5)
Family history, n (%) 56 (38.4) 
Smoking, n (%) 53 (36.3) 
Alcohol consumption, n (%) 36 (24.7) 
ASA,  n (%) 31 (21.2) 
ACE  inhibitor, n (%) 45 (30.8) 
ARB,  n (%) 16 (11) 
Beta  blocker, n (%) 29 (19.9)
Ca  channel blocker, n (%) 25 (17.1) 
Statin, n (%) 16 (11) 
Fibrate, n (%) 17 (11.6) 
EF  (%) 60.5 ± 3.8 
BMI  (kg/m2) 26.69 ± 2.84 
Fasting glucose (mg/dL) 107.19 ± 19.99 
Urea  (mg/dL) 26.08 ± 6.55 
Creatinine (mg/dL) 0.92 ± 0.11 
AST  (U/L) 24.13 ± 6.78 
ALT  (U/L) 22.44 ± 8.29 
Uric  acid (mg/dL) 5.18 ± 0.99 
Total  cholesterol (mg/dL) 185.78 ± 27.59 
LDL-cholesterol (mg/dL) 121.05 ± 21.47 
HDL-cholesterol (mg/dL) 43.87 ± 6.64 
Triglyceride (mg/dL) 123.23 ± 37.45 
TIMI  frame count
LAD 46.54 ± 2.44 
LAD  corrected 27.38 ± 1.43 
RCA  31.63 ± 3.34 
LCX  33.38 ± 3.69 
Mean  31.07 ± 3.38 
Coronary artery branches including SCF (n = 207)
LAD, n 130
RCA, n 46
LCX, n 31
orrected TIMI-LAD is equal to TIMI-LAD/1.7. Mean TIMI equals (TIMI-LAD + TIMI-RCA +
ngiotensin receptor blocker; Ca, calcium; EF, ejection fraction; BMI, body mass index
ipoprotein; HDL, high-density lipoprotein; TIMI, thrombolysis in myocardial infarction; L
oronary ﬂow.iology 63 (2014) 112–118
as mean ± standard deviation (SD). The Shapiro–Wilk test was  used
to determine normality. The Mann–Whitney U-test was used for
two-group comparisons. Pearson’s and Yate’s chi-squared tests
were used to compare categorical variables. Multivariate logistic
regression analysis was  used to identify the independent predic-
tors of SCF. Univariate analysis was performed using age, gender,
body mass index (BMI), smoking, ASA (acetylsalicylic acid) use,
WBC, RDW, PCT group, and PDW as variables. Signiﬁcant variables
(p < 0.05) were included in a multivariate model. Values of p < 0.05
were considered to indicate signiﬁcance. A cutoff point for PCT and
RDW to predict the SCF phenomenon was  calculated with a receiver
operating characteristics (ROC) curve analysis and is expressed as
the area under the curve (AUC) and sensitive-speciﬁc values with
95% conﬁdence intervals (CIs).
Results
The demographic and biochemical data of the two groups are
shown in Table 1. For the 146 patients with SCF (mean age,
58.4 ± 10.3 years; 68.5% male), mean PCT was 0.214 ± 0.40% and
mean RDW was  13.68 ± 1.42%. Compared with the normal artery
group, the SCF group had a higher percentage of smokers [36.3%
(53 patients) vs. 25% (37 patients), p = 0.036] and a higher BMI
(26.69 ± 2.84 vs. 26.07 ± 3.15, p = 0.049). No differences in the bio-
chemical parameters were observed between the two groups.
Table 2 shows a comparison of the 22 complete blood count
parameters between the two groups. The following parameters
Normal coronary artery group (n = 148) p-Value
57.2 ± 9.2 0.387
102 (68.9) 0.937
66 (44.6) 0.103
39 (26.4) 0.739
60 (40.5) 0.107
42 (28.4) 0.070
37 (25) 0.036
27 (18.2) 0.180
46 (31.1) 0.055
46 (31.1) 0.962
19 (12.8) 0.751
38 (25.7) 0.235
32 (21.6) 0.329
22 (14.9) 0.318
23 (15.5) 0.330
59.8 ± 4.0 0.147
26.07 ± 3.15 0.049
108.32 ± 21.94 0.813
27.55 ± 8.69 0.151
0.90 ± 0.11 0.240
23.47 ± 7.47 0.317
23.78 ± 8.22 0.067
5.06 ± 0.79 0.901
184.52 ± 27.27 0.364
124.26 ± 23.97 0.090
45.69 ± 8.78 0.051
123.85 ± 45.48 0.620
33.09 ± 2.32 <0.001
19.46 ± 1.36 <0.001
20.34 ± 2.38 <0.001
21.68 ± 2.54 <0.001
25.01 ± 1.95 <0.001
 TIMI-LCX)/3. ASA, acetylsalicylic acid; ACE, angiotensin-converting enzyme; ARB,
; AST, aspartate transaminase; ALT, alanine aminotransferase; LDL, low-density
AD, left anterior descending; RCA, right coronary artery; LCX, circumﬂex; SCF, slow
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Table  2
Comparison of 22 parameters complete blood count values between two groups.
Slow coronary ﬂow group (n = 146) Normal coronary artery group (n = 148) p-Value
WBC  (×103 mm–3) 7.52 ± 1.43 7.01 ± 1.42 0.002
RBC  (×106 mm–3) 4.76 ± 0.47 4.74 ± 0.46 0.684
HGB  (g/dL) 14.26 ± 1.24 14.23 ± 1.30 0.859
HCT  (%) 41.78 ± 3.55 41.60 ± 3.85 0.671
MCV  (fL) 87.75 ± 5.51 87.92 ± 4.82 0.656
MCH  (pg) 30.18 ± 2.06 30.19 ± 1.87 0.865
MCHC (g/dL) 34.13 ± 0.79 34.20 ± 0.90 0.816
RDW  (%) 13.68 ± 1.42 13.15 ± 1.13 <0.001
PLT  (×103 mm–3) 250.29 ± 50.96 226.10 ± 38.02 <0.001
MPV  (fL) 8.63 ± 1.10 8.22 ± 0.83 <0.001
PCT  (%) 0.214 ± 0.40 0.184 ± 0.29 <0.001
PDW  (%) 16.58 ± 0.76 16.45 ± 0.57 0.028
Lym# (×103 mm–3) 2.24 ± 0.82 2.10 ± 0.61 0.232
Mo#  (×103 mm–3) 0.60 ± 0.26 0.60 ± 0.27 0.852
Neu# (×103 mm–3) 4.44 ± 1.25 4.12 ± 1.24 0.029
Eo#  (×103 mm–3) 0.20 ± 0.19 0.17 ± 0.18 0.265
Ba#  (×103 mm–3) 0.04 ± 0.16 0.02 ± 0.04 0.277
Lym%  29.82 ± 9.04 30.55 ± 8.64 0.419
Mo%  7.74 ± 2.36 8.32 ± 2.67 0.080
Neu%  59.07 ± 10.02 57.91 ± 9.81 0.316
Eo%  2.65 ± 2.39 2.10 ± 1.75 0.059
Ba%  0.57 ± 0.41 0.50 ± 0.40 0.127
WBC, white blood cell count; RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell
hemoglobin concentration; RDW, red cell distribution width; PLT, platelet count; MPV, mean platelet volume; PCT, plateletcrit; PDW, platelet distribution width; Lym#,
lymphocyte count; Mo#, monocyte count; Neu#, neutrophil count; Eo#, eosinophil count; Ba#, basophil count; Lym%, lymphocyte percentage; Mo%, monocyte percentage;
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ere signiﬁcantly higher in patients with SCF than in patients
ith normal coronary arteries: WBC  (7.52 ± 1.43 × 103 mm–3
s. 7.01 ± 1.42 × 103 mm–3, p = 0.002), RDW (13.68 ± 1.42% vs.
3.15 ± 1.13%, p < 0.001), PLT (250.29 ± 50.96 × 103 mm–3 vs.
26.10 ± 38.02 × 103 mm–3, p < 0.001), PCT (0.214 ± 0.40% vs.
.184 ± 0.29%, p < 0.001), MPV  (8.63 ± 1.10 fL vs. 8.22 ± 0.83 fL,
 = 0.001), PDW (16.58 ± 0.76% vs. 16.45 ± 0.57%, p = 0.028),
nd neutrophil count (4.44 ± 1.25 × 103 mm–3 vs. 4.12 ± 1.24 ×
03 mm–3, p = 0.029).
A ROC analysis was performed for all platelet parameters and
DW. The PCT cutoff value was 0.200 (AUC: 0.715; p < 0.001; 95% CI:
.656–0.773; 66% sensitivity; 72% speciﬁcity) (Fig. 2). All patients
ere categorized into two groups according to their PCT value:
atients with PCT <0.200 were assumed to be PCT negative, and all
thers were assumed to be PCT positive. The RDW cutoff value was
3.15 (AUC: 0.636; p < 0.001; 95% CI: 0.572–0.699; 58% sensitivity;
7% speciﬁcity) (Fig. 3).
Age, gender, BMI, smoking, ASA use, WBC, RDW, PDW, and PCT
roup (PCT negative or positive according to the cutoff value) were
nalyzed in a univariate analysis. Smoking, RDW, WBC, and PCT
roup were included in a multivariate logistic regression analy-
is (Table 3). A positive PCT value [odds ratio (OR): 4.165; 95% CI:
.493–6.959, p < 0.001] and RDW (OR: 1.304; 95% CI: 1.034–1.645,
 = 0.025) were independent predictors of the SCF phenomenon.
iscussion
The SCF phenomenon is observed on coronary angiography
s a delayed distal vessel opaciﬁcation in the absence of sig-
iﬁcant coronary stenosis. The mechanism of this angiographic
linical entity remains unknown, although several hypotheses have
een proposed, including inﬂammation, endothelial dysfunction,
hanges in blood rheological properties, increased uric acid, and
onditions associated with increased platelet volume [14–17]. The
ellular components of the blood in patients with SCF have not been
valuated comprehensively.
In our study, 22 complete blood count parameters were com-
ared between patients with the SCF phenomenon and thosewith normal coronary artery ﬂow. Similar to previous reports,
the MPV  was  higher in the SCF group than in the normal artery
group in the present study [18,19]. Platelets play critical roles
in inﬂammation, thrombosis, and cardiovascular physiopathology.
Additionally, increased MPV  is associated with acute coronary
syndrome, carotid artery disease, sepsis, deep vein thrombosis, pul-
monary embolism, and coronary collateral vessels [20–25]. Only
MPV  and platelet count have been evaluated in most earlier inves-
tigations of SCF parameters, and PDW and PCT, which reﬂect the
total platelet mass, have been ignored. PCT has been assumed to
indicate the number of circulating platelets in a unit volume of
blood, analogous to the hematocrit for erythrocytes [26]. Sahin
et al. demonstrated that PCT is correlated with C-reactive protein
(CRP) levels in patients with chronic inﬂammatory diseases such as
tuberculosis [27].
In addition to an increased RDW value, PDW was signiﬁcantly
higher in the SCF group than in the normal artery group. Some
studies have suggested that PDW is more speciﬁc than MPV  for
indicating platelet activation. Vagdatli et al. reported that PDW is
a simple, practical, and speciﬁc activation marker for coagulation
[28]. However, insufﬁcient data on the clinical signiﬁcance of PDW
are available. Increased distribution width of red and white blood
cells may  be associated with impaired deformability of these cells
and thus increased microvascular resistance [29–31].
RDW is a marker of the variation in erythrocyte shape and mor-
phology. Hemolysis and various nutritional deﬁciencies, such as
iron, vitamin B12, and folate deﬁciencies, may increase the RDW
value. Regardless of the hemoglobin level, an increased RDW has
predictive importance for mortality and morbidity in terms of
atherosclerotic disease and heart failure [32,33]. The relationship
between RDW and SCF has been shown in only one study, which
found, similar to our study, that RDW was  an independent pre-
dictor of the SCF phenomenon [34]. The presence of a signiﬁcant
correlation between increased RDW and high-sensitivity CRP lev-
els suggests that RDW may  be a useful marker associated with
inﬂammation [35].
In our study, although the WBC  count was  within the normal
range in both groups, WBC  and neutrophils were present in
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Fig. 2. Receiver operating characteristics (ROC) analysis of all platelet parameters. AUC, area under the curve; PCT, plateletcrit; MPV, mean platelet volume; PLT, platelet
count;  PDW, platelet distribution width.
Fig. 3. Receiver operating characteristics (ROC) analysis of red cell distribution width. RDW, red cell distribution width; AUC, area under the curve.
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Table  3
Independent predictors of slow coronary ﬂow in multivariate logistic regression analysis.
Variables Univariate analysis Multivariate analysis
OR 95% CI p-Value OR 95% CI p-Value
Age 1.012 0.989–1.037 0.305
Gender 0.980 0.599–1.605 0.937
BMI  1.072 0.992–1.158 0.079
Smoking 1.710 1.035–2.825 0.036 1.506 0.869–2.611 0.145
ASA  use 0.598 0.353–1.013 0.056
WBC  1.280 1.087–1.507 0.003 1.145 0.959–1.368 0.135
RDW  1.445 1.161–1.799 0.001 1.304 1.034–1.645 0.025
PCT  positive group 5.011 3.050–8.232 <0.001 4.165 2.493–6.959 <0.001
PDW  1.361 0.948–1.954 0.095
BMI, body mass index; ASA, acetylsalicylic acid; WBC, white blood cell count; RDW, red cell distribution width; PCT, plateletcrit – PCT group, patients with PCT <0.200 were
assumed to be PCT negative and all others were assumed to be PCT positive; PDW, platelet distribution width.
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[igniﬁcantly higher numbers in the SCF group compared with the
ormal artery group. These increases along with the increased
DW suggest that SCF is a subclinical inﬂammatory condition.
onclusions
To the best of our knowledge, our study is the ﬁrst that inves-
igates the predictive value of PCT in patients with SCF. Platelets
re associated with inﬂammation and cardiovascular events. Many
tudies regarding the SCF phenomenon have investigated only
ean platelet volume and platelet count among the possible SCF
arameters. In this study, for the ﬁrst time, patients with SCF were
ompared with patients who had normal coronary artery ﬂow,
ccording to 22 complete blood count parameters, including PCT
nd PDW. The PCT cutoff value for SCF in our study was 0.200. Pos-
tive PCT value (>0.200) and RDW were independent predictors of
CF. In patients with SCF phenomenon, positive PCT may  be used as
 marker for more aggressive antiplatelet treatment. For patients
ith positive PCT (over 0.200), whether recovery of slow coro-
ary ﬂow to normal coronary ﬂow after antiplatelet therapy will
e another area of study. Further large-scale and comprehensive
tudies are needed to support these results.
imitations
Because high-sensitivity CRP is not evaluated routinely in
atients undergoing elective coronary angiography in our depart-
ent, this test was not included to compare inﬂammatory status
etween the groups. Owing to the retrospective nature of this study,
o patient was evaluated by intravascular ultrasonography. For this
eason, the existence of minimal atherosclerotic plaques could not
e deﬁnitively ruled out.
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